Sinopharm got approval last week to conduct clinical trials on a recombinant protein vaccine. Photo: AFP
Coronavirus: China has cheaper vaccine technologies joining the race to beat the pandemic
- Protein subunit vaccines are considered safe and cheaper than inactivated vaccines and could fill the production gap
- China considers combining vaccines or extending intervals to increase protection against Covid-19
Topic |
Chinese coronavirus vaccines
Sinopharm got approval last week to conduct clinical trials on a recombinant protein vaccine. Photo: AFP
